Vertex Pharmaceuticals Incorpo

VRTX 
(NASDAQ) 
 
$ 173.78
Updated 01:00:00
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 642,782
High $ 174.37
Low $ 167.63
Open $ 172.98
ISIN
Prev close $ 172.21
# of shares 255.56M
Market cap 44,411M USD
Intraday

Market closed
Vertex Pharmaceuticals Incorpo
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  173.78 -2.3% Stock price decreasing -3.7% Stock price decreasing -2.7% Stock price decreasing 16.9% Stock price increasing 22.7% Stock price increasing
Powered by TradingView

News about Vertex Pharmaceuticals Incorpo

  • English
  • Regulatory news

Company profile

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, and Symdeko for cystic fibrosis, in addition to several mid- and late-stage products targeting this market. Vertex successfully developed and commercialized two HIV protease inhibitors, which were outlicensed to GlaxoSmithKline. Vertex's pipeline also includes therapies for the treatment of cancer, pain, inflammatory diseases, influenza, and other rare diseases.

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
11 December 2018 09:54:22
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181207.1 - EUROWEB3 - 2018-12-11 10:54:22 - 2018-12-11 09:54:22 - 1000 - Website: OKAY